Drug Profile
Research programme: FLT3 inhibitors - MaxoCore
Alternative Names: FLT3 kinase inhibitors research programme - MaxoCore; MC-2002; MC-2006Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator MaxoCore Pharmaceuticals
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
- 12 Jan 2011 This programme is in active development
- 07 Dec 2010 Research programme: FLT3 inhibitors - MaxoCore is available for licensing as of 07 Dec 2010. http://www.maxocore.com